Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Berger

Showing results (1-10 of 239) with videos related to

Pageof 24
Sort By:
Journal of the American College of Cardiology|April 23, 2003
Can euphoria be bad?Peter B Berger
Disease-A-Month : DM|July 24, 2012
Assessment of advantages and disadvantages of agents used for therapeutic anticoagulationPeter B Berger
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 23, 2004
Resistance to antiplatelet drugs: is it real or relevant?Peter B Berger
JACC. Cardiovascular Interventions|March 12, 2016
Response to a Differing Perspective: The Real Issues Related to Public Reporting Around Percutaneous Coronary InterventionPeter B Berger
ACP Journal Club|September 3, 2004
Percutaneous transluminal coronary angioplasty improved long-term angina status more than medical therapy in coronary artery diseasePeter B Berger
Circulation. Cardiovascular Quality and Outcomes|January 15, 2015
Should proton pump inhibitors be withheld from patients taking clopidogrel? The issue that has been giving me heartburn!Peter B Berger
The New England Journal of Medicine|September 2, 2015
Finding the Proper Context for the MATRIX TrialPeter B Berger
Current Controlled Trials in Cardiovascular Medicine|November 21, 2001
Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?Peter B Berger
Journal of the American College of Cardiology|July 31, 2010
The glycoprotein IIb/IIIa inhibitor wars: an updatePeter B Berger
ACP Journal Club|July 2, 2005
Reviparin reduced a composite endpoint of death, reinfarction, stroke, and ischemia at 7 and 30 days after acute MIPeter B Berger
Pageof 24

Showing results (1-10 of 239) with videos related to

Sort By:
Pageof 24
Journal of the American College of Cardiology|April 23, 2003
Can euphoria be bad?Peter B Berger
Disease-A-Month : DM|July 24, 2012
Assessment of advantages and disadvantages of agents used for therapeutic anticoagulationPeter B Berger
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 23, 2004
Resistance to antiplatelet drugs: is it real or relevant?Peter B Berger
JACC. Cardiovascular Interventions|March 12, 2016
Response to a Differing Perspective: The Real Issues Related to Public Reporting Around Percutaneous Coronary InterventionPeter B Berger
ACP Journal Club|September 3, 2004
Percutaneous transluminal coronary angioplasty improved long-term angina status more than medical therapy in coronary artery diseasePeter B Berger
Circulation. Cardiovascular Quality and Outcomes|January 15, 2015
Should proton pump inhibitors be withheld from patients taking clopidogrel? The issue that has been giving me heartburn!Peter B Berger
The New England Journal of Medicine|September 2, 2015
Finding the Proper Context for the MATRIX TrialPeter B Berger
Current Controlled Trials in Cardiovascular Medicine|November 21, 2001
Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?Peter B Berger
Journal of the American College of Cardiology|July 31, 2010
The glycoprotein IIb/IIIa inhibitor wars: an updatePeter B Berger
ACP Journal Club|July 2, 2005
Reviparin reduced a composite endpoint of death, reinfarction, stroke, and ischemia at 7 and 30 days after acute MIPeter B Berger
Pageof 24